The chronic inflammatory environment associated with systemic lupus erythematosus can lead to an accelerated immunosenescence responsible for the endothelial damage and increased cardiovascular risk observed in these patients. 
subset, in 84 systemic lupus erythematosus patients and 46 healthy controls. Also, 48 rheumatoid arthritis patients and 72 individuals with traditional cardiovascular risk factors participated as disease controls. Phenotypic characterization of CD28 + and CD28 null cells was performed by analyzing markers of senescence (CCR7, CD27, CD57) and cytotoxicity (CD56, perforin, granzyme B, IFN-g). IL-1b, IL-6, IL-8, IL-10, IL-12, IL-17A, IFN-a, IFN-g, TNF-a, B lymphocyte stimulator, and GM-CSF serum levels were analyzed in systemic lupus erythematosus patients and healthy controls. CD4 + CD28 null cells were notably increased in the systemic lupus erythematosus patients and disease controls compared with healthy controls. In contrast, angiogenic T cells were only reduced in the disease controls (those with rheumatoid arthritis or traditional cardiovascular risk factors). Nevertheless, an anomalous presence of CD28 nullangiogenic T cells, with cytotoxic and senescent characteristics, was noted in systemic lupus erythematosus patients in association with anti-dsDNA titer, anti-SSA/Ro antibodies and circulating TNF-a, IL-8, IFN-a, and B lymphocyte stimulator amounts. This subset was also detected in those with traditional cardiovascular risk factors but not in the rheumatoid arthritis patients. In contrast, CD28
Introduction SLE is an autoimmune disease characterized by a dysregulation of the immune system involving lymphocyte overactivation and autoantibody production, which drive chronic inflammation and consequent tissue damage [1, 2] . Accumulating evidence has suggested the chronic proinflammatory environment and repeated cell stimulation in autoimmune patients can lead to accelerated aging of the immune system, known as premature immunosenescence [3] [4] [5] [6] . The progressive age-related deterioration of the lymphocyte compartment is associated with a decline in the proportion of CD4 + cells and an increase in terminally differentiated T cells that have lost CD28 expression [3, 7] . In addition to elderly subjects, expansion of CD4 + CD28 null cells has been reported in a variety of conditions, including patients with autoimmune and CV diseases [7] [8] [9] [10] [11] [12] [13] and could be considered a marker of immunosenescence itself. Functionally, CD4 + CD28 null T cells secrete inflammatory mediators and release cytolytic molecules from intracellular granules capable of inducing damage in endothelial cells [12, 14] . CD4 + CD28
null cells can migrate into inflamed tissue and play an important role in destabilizing atherosclerotic plaques [15] .
Endothelial damage, accelerated atherosclerosis, and increased CV disease are well-recognized complications of SLE that cannot be completely explained by traditional risk factors [16] . Thus, a number of disease-specific features, including chronic inflammation, a dysregulated cytokine profile, and altered T cell subsets, have been proposed as important triggers of the imbalance between endothelial damage and repair that underlie the CV disorders developing in those with SLE [17] .
Given this scenario, special interest should be given to a recently identified T cell population, T ang cells, which promote repair of damaged endothelium by cooperating with endothelial progenitor cells [18] . T ang cells are characterized by the expression of the platelet endothelial cell adhesion molecule (CD31) and the receptor for stromal-derived factor 1 (CXCR4) and the secretion of angiogenic molecules [18] . A decrease in T ang frequency has been associated with vascular disease [19] , and we have recently described a reduction of this subpopulation in the circulation of RA patients, which was especially stronger in those presenting with CV disease [20] .
Premature aging of the immune system seems to play a role in the development of CV disorders in autoimmune patients .  Thus, the aim of the present work was to analyze 2 populations  with opposite effects on vascular endothelium, T ang , and  CD4  + CD28  null cells, in relation to clinical features and soluble factors associated with inflammation or endothelial damage in SLE patients.
MATERIALS AND METHODS

Patients and controls
A total of 84 SLE patients fulfilling the ACR criteria for SLE [21] were recruited from the Autoimmune Disease Unit (Hospital Universitario Central de Asturias, Oviedo, Spain). Information on the clinical manifestations, traditional CV risk factors, and CV disorders during the disease course were obtained after a review of the clinical histories, and the parameters of disease activity and treatments were recorded at sampling ( -T ang subsets was performed in 20 SLE patients by extracellular staining with anti-CCR7-PE (BD Biosciences), CD27-APC, CD56-APC, or CD57-PE or the corresponding isotype controls (Miltenyi Biotec, Bergisch Gladbach, Germany). Additionally, blood cells were intracellularly stained with perforin-Pacific Blue, granzyme B-PE (Miltenyi Biotec), and IFN-g-PE (BD Biosciences). A minimum of 20,000 CD3 + cells per tube was acquired using a FACSCanto II flow cytometer (BD Biosciences) and analyzed using FlowJo software (Tree Star, Ashland, OR, USA). The specific fluorescence intensity was quantified as the mean fluorescence intensity calculated by subtracting the background of isotype-matched control staining from the total fluorescence intensity.
Cytokine quantification
IFN-a, IL-10, IL-6, IL-12, IL-1b, IL-17A, and GM-CSF were analyzed by Cytometric Bead Arrays (BD Biosciences) in accordance with the manufacturer's instructions. ELISA kits were used for TNF-a (PeproTech, Rocky Hill, NJ, USA), BLyS (eBioscience, San Diego, CA, USA), and IFN-g (BD Biosciences).
Statistical analysis
The Kolmogorov-Smirnov test was used to evaluate normality. Data are expressed as the median (interquartile range). Differences between the disease and control groups were assessed using the nonparametric MannWhitney U test. Because comparisons were performed between groups with different sample sizes, Hedge's g statistic was calculated for each reported significant difference between the groups (g values .0.5 and .0.8 were considered to indicate a medium and large effect, respectively) [22] . Statistically significant differences in cytotoxic and senescence marker expression among CD28 null T cell and CD28 null/pos T ang cell subpopulations were evaluated using the Friedman test and Dunn's post test. Linear regression analyses adjusted for sex and age and multiple backward regression models were applied to determine the influence of demographic and disease features in different cellular populations or serum factors using logarithmic transformations of non-normal variables. Thus, age at diagnosis, disease duration, SLE disease activity index, clinical manifestations (e.g., malar rash, discoid lesions, photosensitivity, oral ulcers, arthritis, serositis, cytopenia, renal disorder, neurologic disorder) and autoantibodies presence (antinuclear antibodies, anti-dsDNA, anti-SSA, anti-SSB, anti-Sm, anti-RNP, rheumatoid factor, anti-cardiolipin) were entered into the initial model. GraphPad Prism, version 5 (GraphPad, La Jolla, CA, USA), and SPSS, version 22.0 (IBM, Armonk, NY, USA), software packages were used for all determinations, and P , 0.05 was considered significant. Data presented as n (%) or mean 6 SD. ANAs, antinuclear antibodies; BMI, body mass index; NSAIDs, nonsteroidal anti-inflammatory drugs; RF, rheumatoid factor; SLEDAI, SLE disease activity index.
a Azathioprine, mycophenolate mofetil.
b Coronary heart/artery disease, cerebrovascular accidents, congestive heart failure, peripheral vascular disease, angina, myocardial infarction.
RESULTS
Senescent phenotype of T ang cells in SLE patients
null and T ang (CD3 + CD31 + CXCR4 + ) populations were quantified in the SLE, HC, and disease control groups with expected low T ang levels (RA patients and tCVR individuals) by flow cytometry (Fig. 1) . The results showed a significant increase of CD4 + CD28
null cells in those with RA and tCVR and, more strikingly, in SLE patients compared with HCs ( Fig. 2A) , supporting a disease-associated immunosenescence. However, no significant differences were observed in the frequency of T ang cells between the SLE patients and HCs, although this population was notably reduced in both disease control groups. However, the absolute T ang counts were slightly reduced in SLE patients compared with HCs [median 6.59 (range 2.91-11.91) vs. median 8.89 (range 5.23-15.26) cells/ml; P = 0.048], because most patients with SLE tend to present with lymphopenia.
Additional analysis of the T ang cell population showed that .20% of total T ang cells in SLE patients did not express CD28. This anomalous subset, named CD28 null -T ang , was also observed in tCVR individuals but were nearly absent in the HCs and RA patients (Fig.  2B) , pointing out relevant differences in the T ang profile of RA and SLE. Multiple linear regression analyses adjusted for sex and age showed that CD28 In contrast, the frequency of CD28 + -T ang cells in the SLE patients was similar to that of the HCs, but the RA and tCVR 
(C) T ang populations in SLE patients with cardiovascular disorders (CVD) or tCVR compared with the rest of the patients (CV free). (D) Percentage of CD4
+ cells among CD28 + and CD28 null -T ang subpopulations in patients and controls. Horizontal lines represent median and interquartile range. Statistical significance was assessed using the Mann-Whitney U test. (Fig. 2C ). CD28 + -T ang cells were significantly reduced in SLE patients with CV disease compared with the levels in HCs (P = 0.008). No significant differences in total T ang cells or their subsets were detected in SLE, RA, or tCVR groups, according to their CV risk factor. The proportion of CD4 + lymphocytes among the CD28 + -T ang subset was reduced in tCVR individuals and, in particular, in SLE patients. In contrast, the opposite occurred among the CD28 null -T ang cells (Fig. 2D) . Therefore, T ang cells from SLE patients, even those expressing CD28, seem to exhibit an altered phenotype.
Characterization of CD28 null -T ang cells
Next, we wanted to determine whether the downregulation of CD28 expression in a subset of SLE T ang cells was accompanied by other senescent features. Thus, we performed a phenotypic characterization of CD28 null -and CD28 + -T ang subsets in SLE patients (n = 20) by analyzing the expression of a range of cytotoxic and senescent markers usually present in CD28 null T cells (Fig. 3) . The results showed that CD28 null -T ang cells expressed perforin, granzyme B, and CD56, similar to the expression in the whole CD3 + CD28 null population, as well as significant levels of IFN-g, thus suggesting a cytotoxic and inflammatory ability of this subset. Likewise, the expression of CCR7, CD27, and CD57 markers supported the senescent profile of CD28 null -T ang cells. As expected, CD28 + -T ang cells did not exhibit these cytotoxic and senescent characteristics.
Serum cytokines associated with CD28 null cells
The senescent profile of T ang cells from SLE patients suggests they could exert a proinflammatory, rather than a protective, effect on endothelial cells. Therefore, to estimate the possible harmful role of CD4 + CD28 null and CD28 null -T ang cells in SLE, we analyzed these subpopulations in relation to several cytokines and chemokines quantified in the serum of SLE patients and HCs ( Table 3) . Most of the analyzed molecules were significantly altered in the SLE patients, according to the wide rang of SLE dysregulation. Linear regression analyses adjusted by age and sex revealed significant positive associations of both CD4 + CD28
null and CD28 null -T ang subsets with several proinflammatory mediators in HCs and SLE patients ( Table 4) . Moreover, analyses of significantly increased cytokines using a multiple backward regression model that included the demographic and clinical features of SLE patients as covariates confirmed the associations of both CD4 + CD28
null and CD28 null -T ang subsets with higher circulating amounts of the inflammatory mediators TNF-a and IL-8 ( Table 5) . Additionally, CD28 null -T ang cells increased with increasing levels of BLyS and IFN-a, 2 cytokines with particular relevance to SLE activity. Therefore, all CD28 null cells were associated with an inflammatory environment, but the CD28 null -T ang subset seems to be, in addition, closely related to SLE pathology.
DISCUSSION
The present work provides the first evidence for the presence, in pathologic conditions, of a proportion of T ang cells with a senescent and cytotoxic profile (CD28 null -T ang ). Thus, the inclusion of CD28 positivity as a new marker for the true T ang population is proposed. In agreement with the low levels of total and CD28 + -T ang cells exhibited by our tCVR and RA groups, a reduced T ang population has been previously described in CV conditions [8] and in RA patients, especially those who had experienced a CV event [20] . In line with this, SLE patients presenting with CV disorders showed a significant decrease in the true CD28 + -T ang population, and the senescent CD28 null -T ang subset increased even in the CV-free SLE group. The reduced proportion of CD4 + lymphocytes within the CD28 + -T ang subset in SLE patients is in accordance with a senescent profile and suggests impaired function. Moreover, this alteration was also observed in tCVR individuals, the other disease group with increased CD28 null -T ang cell levels and usually characterized by premature immunosenescence [13, 23] .
An expansion of CD4 + CD28 null cells, most of them autoreactive, has been reported in several autoimmune diseases [3, 7, 9, 20] . It has been suggested that they could enhance autoimmunity through the production of proinflammatory cytokines that might activate autoreactive T cells [24] . Given the striking increase of circulating CD4 + CD28 null cells found in SLE patients, and to a lesser extent in RA patients and tCVR individuals, the presence of CD28
null -T ang cells should not be surprising. However, this subset was almost absent in RA patients, ruling out a general condition present in autoimmune diseases. Alternatively, this might be explained by the migration of T ang blood cells (regardless of CD28 expression) to the inflamed joints, where they could be involved in the aberrant synovial angiogenesis present in these patients [25] . It has been suggested that this migration could underlie the low circulating T ang counts and the chronic inflammation detected in RA patients with active disease [20] . In contrast, although both total and CD28 + -T ang cells were decreased in the tCVR group, the CD28 null -T ang subset was notably augmented. Therefore, the T ang profile seems to be disease specific, highlighting the complexity of this poorly understood cell population.
It has been shown that CD4 + CD28 null cells, which produce large amounts of inflammatory cytokines, can be isolated from ruptured atheromas [12, 15] . Thus, we hypothesized that the CD4 + CD28 null -T ang subset reported in the present study could have a proatherogenic role. Accordingly, the proportion of CD4 + T cells among the CD28 null -T ang subset was significantly increased in both tCVR and SLE groups. However, CD28 null -T ang cells, in view of their senescent and cytotoxic phenotype, might be expected to have a deleterious, rather than a protective, effect on endothelial cells. This population was related to higher levels of TNF-a and IL-8, similar to CD4 + CD28 null cells, but also to several SLE features, including increased levels of IFN-a, BLyS, anti-dsDNA titer, and anti-SSA antibodies, which were associated with endothelial damage and a poor prognosis. Therefore, senescent CD28 null -T ang cells could amplify the damage caused in SLE by the action of IFN-a, BLyS, and anti-dsDNA antibodies in a vicious circle [26] .
In conclusion, our results have revealed the existence of an aberrant CD28 null -T ang population in SLE patients. This aberrant population is characterized by a senescent and cytotoxic phenotype, which was associated with anti-dsDNA titer and an increased production of proinflammatory mediators. It is also associated with other SLE-related pathogenic factors involved in endothelial dysfunction and cardiovascular disease, such as IFN-a or BLyS. Therefore, blocking these molecules in patients with high CD28 null -T ang levels could reduce the premature immunosenescence and accelerated atherosclerosis characteristic of most SLE patients. 
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